Celltrion Healthcare Australia and Juno Pharmaceuticals Australia Partner on Biosimilars

SYDNEY, AUSTRALIA – Celltrion Healthcare Australia (Celltrion) and Juno Pharmaceuticals (Juno) have entered in to a co-marketing partnership, covering the biosimilar products Herzuma (biosimilar trastuzumab), and Truxima (biosimilar rituximab). Celltrion Healthcare Australia, a division of the biosimilar developer Celltrion Healthcare, are the Marketing Authorisation holders in Australia for these and other biosimilar brands and will distribute the products in the market. Juno as a leading supplier into hospitals, has been appointed to provide sales promotion and hospital contracting services to Australian Hospital market customers.

Commenting on this partnership, Cecilia Sung – Country Manager ANZ stated that Celltrion Healthcare Australia is pleased with the opportunity to partner with Juno Pharmaceuticals to offer our global biosimilar brands to Australian Healthcare professionals and patients, with a blend of quality & economic benefits. We are also confident that with an extensive commercial network, strong customer relationships and established hospital market presence by Juno Pharmaceuticals, Biosimilar brands from Celltrion Healthcare will achieve high customer acceptance as they have been in regulated markets such as EU/ USA.    

“We are excited that Celltrion has chosen Juno to represent their rituximab and trastuzumab products in Australia. The Juno team has very extensive experience with biosimilars in the Australian marketplace over the last decade” says Mark Crotty, CEO Juno Australia.

Juno Pharmaceuticals Acquires Noradrenaline 2 mg/2 mL & 4 mg/4 mL from Mayne Pharma

MELBOURNE, AUSTRALIA – Juno Pharmaceuticals is pleased to announce the acquisition of noradrenaline 2 mg/2 mL and 4 mg/4 mL concentrated injection from Mayne Pharma; an important addition to Juno’s growing range of vasopressors and critical care medicines.

As part of the acquisition, Juno will receive the intellectual property and regulatory approvals for NORADRENALINE MYX 2 mg/2 mL concentrated solution for injection ampoule and NORADRENALINE MYX 4 mg/4 mL concentrated solution for injection ampoule, along with associated contracts and agreements.

This acquisition is Juno’s second for 2019 and is another milestone in Juno’s continued growth and vision to be the leader in supply of off-patent products in hospitals across Australia and New Zealand.

Our focus on hospital injectable medicines and hospital customers makes us ideally placed to supply this product in the Australian market, noted Juno CEO & Managing Director, Mark Crotty. It is exciting to see our range of hospital products growing rapidly, customers see us as their trusted partner in this area.

The agreement comes into effect on July 16^th, 2019 and Juno’s Key Account Managers will work closely with customers and wholesalers to ensure a smooth transition and continuity of supply. As with all Juno products, continuous, reliable supply is a top priority.

From July 16^th, 2019, all commercial enquiries regarding noradrenaline should be directed to your local Juno representative.  Any adverse event reporting, product complaints and medical enquiries should directed to Juno Medical Information on 1800 620 076 or medical-enquiries@junopharm.com.au

• Noradrenaline product information available here.
• Noradrenaline consumer medicine information available here.

About Juno

Juno Pharmaceuticals is a rapidly growing, local Australian and New Zealand business and are experts in off-patent prescription pharmaceuticals. Juno’s portfolio includes medicines across a diverse range of therapeutic areas, with hospital products the core focus of the business. The acquisition of this portfolio is in line with Juno’s mission to improve the health of society, through delivering high quality products to patients, and value to hospitals, the government and tax payers.

Med263. Prepared July 2019.

Juno Pharmaceuticals Launches Schedule 3 Naloxone Hydrochloride

MELBOURNE, AUSTRALIA – The annual number of deaths due to accidental drug overdose has been increasing steadily over the past 15 years and now exceeds the national road toll.¹ As this number has been increasing, its demographic has been changing, with most drug related deaths now occurring amongst middle aged Australians.¹ Unfortunately, Australia has not escaped the worldwide opioid epidemic, with this category of drugs the cause of most fatal overdoses.¹

In response to this evolving issue, in 2016, naloxone hydrochloride was down-scheduled on the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) from a Schedule 4 (S4) – Prescription Only Medicine to a Schedule 3 (S3) – Pharmacist only Medicine. Naloxone hydrochloride is indicated for the treatment of opioid overdose, therefore this move to facilitate product access has the potential to save many lives.

. The availability of a S3 product will eliminate the current need for pharmacists to over-label the S4 product before dispensing without a prescription. The Junalox pack will also be more consumer friendly, with the addition of an Opioid Overdose Action Plan to the product leaflet. This action plan includes vital information such as:

• How to recognise an overdose
• How to respond during an overdose
• Ste-by-step administration instructions with photos

Juno will continue to supply the S4 product to hospitals, with community pharmacies encouraged to stock the S3 product.

(more…)

Juno Launches New Range of Polypropylene Pre-Filled Syringes

Juno is pleased to announce the launch of their new range of polypropylene pre-filled syringes, supplied by Aguettant, a leading French manufacturer of injectable medicines.

Established in Lyon in 1903, Aguettant remains an independent, family owned company, while growing to have three sites across France and a presence in over 60 countries.

Juno has partnered with Aguettant to supply a number of life-saving medicines to the Australian market. Registered products in the pre-filled syringe range currently include:

• ADRENALINE AGUETTANT 1:10,000 adrenaline (epinephrine) (as acid tartrate) 1 mg/10 mL solution for injection prefilled syringe
• EPHEDRINE AGUETTANT ephedrine hydrochloride 30 mg/10 mL solution for injection pre-filled syringe

Additional products supplied to Juno by Aguettant include:

• SODIUM VALPROATE JUNO sodium valproate 400 mg/4 mL solution for injection, ampoule

This new commercial agreement and range is in line with Juno’s vision to lead the category by improving the way products are developed and delivered to market.

For more information on the new range, please get in touch:

General public: Contact our medical information team
P: 1800 620 076 E: medical-enquiries@junopharm.com.au

Healthcare professionals: Contact your local key account manager

Roz Pelen – VIC/TAS
M: 0417 720 821 E: roz.pelen@junopharm.com.au

Majella McCann – SA/WA/NT
M: 0447 005 868 E: majella.mccann@junopharm.com.au

Jacqui Swan – QLD
M: 0447 575 708 E: jacqui.swan@junopharm.com.au

Mary Abdelmalek – NSW/ACT
M: 0437 053 505 E: mary.abdelmalek@junopharm.com.au

Anita Butko – National
M: 0475426004 E: anita.butko@junopharm.com.au

Med199. Prepared July 2018.

Amneal Portfolio Acquisition

Juno Pharmaceuticals today announced it has acquired the Amneal injectables, ophthalmic, and oncology portfolio. This business primarily has a focus on Australian hospital customers.

“Juno is excited to add the Amneal Australia’s hospital injectable, ophthalmic, and oncology range to its growing portfolio. The Amneal range complements many of the current Juno assets and Juno is particularly excited to be managing products such as Bicnu (carmustine)” says CEO and Managing Director, Mark Crotty.

Juno is a rapidly growing local Australian business which recorded its first full year of commercial sales in 2016. Juno’s business model is based on partnering, including with international and local generic suppliers and innovative discovery companies, and has a focus on local Australian hospital customer needs. The acquisition of select Amneal products is Juno’s first since its formation in 2013. When added to the existing portfolio and strong pipeline, the acquisition positions Juno as one of the largest generic injectable product hospital suppliers in the Australian market.

The acquisition takes effect from August 31st, 2017. Juno will work with Amneal to ensure a smooth transition of the business with suppliers and customers.

For all queries please contact:

Mark Crotty, +61424 152 881